Vitamin B6 treatment of intractable seizures

Vitamin B-6 (VB6)-related seizures include clinical seizures associated with VB6 deficiency and dependency. Both types of seizures are suppressed by VB6. We proposed VB6-responsive seizures as the third category of VB6-related seizures in 1977. Vitamin B6-responsive seizures decrease or disappear in response to high-dose oral VB6. Seizure onset in most of our cases occurred within the first year of life, although this varied between 3 months and 5 years. Etiologically, such cases were not only idiopathic or cryptogenic, but also symptomatic and associated with organic brain lesions. The tryptophan load test was usually negative. Vitamin VB6-responsive seizures or epilepsy were usually West syndrome (WS), however may also include Lennox-Gastaut syndrome, grand mal or partial motor seizures. High-dose VB6 treatment administered to 216 consecutive WS cases had an overall response rate of 100 mg/day, and a dramatic increase in clinical response with high-dose VB6 (100-400 mg). Little clinical response was noted with administration of low dose VB6 (10-30 mg/day). Thus, high-dose oral VB6 treatment is recommended in all WS patients at time of initial treatment for a minimum of 10 days, considering the safety and rapid onset of efficacy, usually within 1 week, of this 13.9%, being hid not only in cryptogenic cases (32%), but also in symptomatic WS (11.5%) associated with identifiable brain pathologies. Notably, responsive patients had excellent long-term seizure and mental outcomes without the need for conventional antiepileptic medication. A gradual increase in clinical response to VB6 was noted with increasing the VB6 dose from 30 to 50 100 mg/day, and a dramatic increase in clinical response with high-dose VB6 (100-400 mg). Little clinical response was noted with administration of low dose VB6 (10-30 mg/day). Thus, high-dose oral VB6 treatment is recommended in all WS patients at time of initial treatment for a minimum of 10 days, considering the safety and rapid onset of efficacy, usually within 1 week, of this treatment. (C) 2011 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.